Envisioning future strategies for vaccination against tuberculosis

Nature Reviews Immunology

Volumn 6, Issue 9, 2006, Pages 699-704

  Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; SUBUNIT VACCINE; TUBERCULIN;

ANTIGENICITY; BCG VACCINATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG SAFETY; HEALTH CARE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MEDICAL RESEARCH; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VACCINATION; WORLD HEALTH ORGANIZATION;

ANIMALS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MYCOBACTERIUM; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 33748047496     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1920     Document Type: Review

References (15)

1. World Health Organization. Global Tuberculosis Control - Surveillance, Planning, Financing (World Health Organization, Geneva, 2004).
2. Koch, R. in Verhandlungen des X. Internationalen Medicinischen Congresses, Berlin, 4-9 August 1890 35-47 (Hirschwald, Berlin, 1891) (in German).
3. Guttstadt, A. Die Wirksamkeit des Koch'schen Heilmittels gegen Tuberculose. Amtliche Berichte der Kliniken, Polykliniken und Pathologisch/Anatomischen Institute der Preussischen Universitäten (Springer, Berlin, 1891) (in German).
4. Calmette, A. Sur la vaccination préventive des enfants nouveau-nés contre la tuberculose par le BCG. Ann. Inst. Pasteur 41, 201-232 (1927) (in French).
5. Calmette, A. La Vaccination Préventive Contre la Tuberculose par le "BCG" (Masson, Paris, 1927) (in French).
6. Reiter, H. Die Säuglingstuberkulose in Lübeck (Springer, Berlin, 1935) (in German).
7. Kaufmann, S. H. E. & McMichael, A. J. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nature Med. 11, S33-S44 (2005).
8. Kaufmann, S. H. E. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 26, 660-667 (2005).
9. Ulrichs, T. & Kaufmann, S. H. E. New insights into the function of granulomas in human tuberculosis. J. Pathol. 208, 261-269 (2006).
10. Walburger, A. et al. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 304, 1800-1804 (2004).
11. Skeiky, Y. A. et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172, 7618-7628 (2004).
12. Olsen, A. W., Williams, A., Okkels, L. M., Hatch, G. & Andersen, P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72, 6148-6150 (2004).
13. McShane, H. et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med. 10, 1240-1244 (2004).
14. Horwitz, M. A., Harth, G., Dillon, B. J. & Maslesa-Galic, S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl Acad. Sci. USA 97, 13853-13858 (2000).
15. Grode, L. et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest. 115, 2472-2479 (2005).